RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-57340 | Pharmaceuticals and Healthcare
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Recurrent Glioblastoma Multiforme Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET
7.1 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Boehringer Ingelheim GmbH
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Boston Biomedical Inc.
16.3 Bristol-Myers Squibb Company
16.4 Cantex Pharmaceuticals Inc.
16.5 Cavion LLC
16.6 Celldex Therapeutics Inc.
16.7 Coherus BioSciences Inc.
16.8 Cortice Biosciences Inc.
16.9 Eisai
16.10 Eli Lilly and Company
16.11 EnGeneIC Ltd
16.12 ERC Belgium SA
16.13 GenSpera Inc.
16.14 Genzyme Corporation
16.15 GW Pharmaceuticals Plc
16.16 ImmunoCellular Therapeutics Ltd.
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeAU-105
Axitinib
AXL-1717
AZD-7451
By Application
Hospital
Clinic
Companies
Boehringer Ingelheim GmbH
Boston Biomedical Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals Inc.
Cavion LLC
Celldex Therapeutics Inc.
Coherus BioSciences Inc.
Cortice Biosciences Inc.
Eisai
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
GenSpera Inc.
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics Ltd.
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.